Eli Lilly and Co (Eli Lilly (LLY)) stock is trading higher on Thursday, and the reason is straightforward: a major insurance milestone that substantially expands consumer access to the company's core obesity portfolio. The broader market is also having a good day, with the Nasdaq up 0.83% and the S&P 500 gaining 0.51%, but Lilly's move is its own story.

PBM Coverage Drives Momentum

Eli Lilly announced that all three of the nation's largest pharmacy benefit managers (PBMs) will cover its complete weight management lineup. Traders are reacting to the increased volume potential after CVS Caremark (CVS (CVS)) confirmed it will reintroduce the popular Zepbound treatment as a covered medication. That's a big deal—when the gatekeepers of drug access say yes, the addressable market suddenly gets a lot bigger.

Implementation Timelines Revealed

The commercial rollout will occur in phases. Coverage for Lilly's once-daily oral option, Foundayo, begins on June 1 under the CVS Caremark Commercial Template. Meanwhile, broader template plan coverage for the injectable Zepbound will resume by October 1, though existing patients will face no coverage interruptions. So if you're already on Zepbound, you can breathe easy.

Improving Patient Affordability

"For too long, effective obesity treatment has been out of reach for the people who need it," stated Ilya Yuffa, executive vice president and president of Lilly USA, in the announcement. Under the updated commercial templates, eligible patients can acquire the medications for $25 a month, while specific Medicare Part D beneficiaries can access a $50 monthly rate via the Medicare GLP-1 Bridge program starting July 1. That's a far cry from the list prices that can run into the thousands.

Critical Levels To Watch for LLY Stock

LLY is extended above its major moving averages, trading 13.5% above the 20-day SMA, 19.2% above the 50-day SMA, and 21% above the 200-day SMA—classic price-leading-the-trend behavior. The 20-day SMA is above the 50-day SMA (bullish), and the golden cross (50-day above 200-day) that formed in November 2025 continues to frame the longer-term uptrend. But momentum is getting stretched: RSI is 70.23, which is technically overbought. That doesn't mean the stock can't go higher, but it does suggest the easy gains might be behind us for now.

• Key Resistance: $1134
• Key Support: $943.50

LLY Price Action: Eli Lilly shares were up 3.48% at $1120.56 at the time of publication on Thursday. The stock is trading near its 52-week high of $1133.95, according to market data.